|
1
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song
J, Zhao X, Huang B, Shi W, Lu R, et al: A Novel coronavirus from
patients with pneumonia in China, 2019. N Engl J Med. 382:727–733.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong
Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al: Early transmission
dynamics in Wuhan, China, of novel coronavirus-infected pneu-monia.
N Engl J Med. 382:1199–1207. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Woo PC, Huang Y, Lau SK and Yuen KY:
Coronavirus genomics and bioinformatics analysis. Viruses.
2:1804–1820. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Wit E, van Doremalen N, Falzarano D and
Munster VJ: SARS and MERS: Recent insights into emerging
coronaviruses. Nat Rev Microbiol. 14:523–534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hasöksüz M, Kiliç S and Saraç F:
Coronaviruses and SARS-COV-2. Turk J Med Sci. 50(SI-1): 549–556.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ashour HM, Elkhatib WF, Rahman MM and
Elshabrawy HA: Insights into the recent 2019 novel coronavirus
(SARS-CoV-2) in light of past human coronavirus outbreaks.
Pathogens. 9:1862020. View Article : Google Scholar :
|
|
7
|
Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan
S and Yuen KY: Genomic characterization of the 2019 novel
human-pathogenic coronavirus isolated from a patient with atypical
pneumonia after visiting Wuhan. Emerg Microbes Infect. 9:221–236.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banerjee A, Kulcsar K, Misra V, Frieman M
and Mossman K: Bats and coronaviruses. Viruses. 11:412019.
View Article : Google Scholar :
|
|
9
|
Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H,
Zhu J, Zhang Q, Wu J and Liu L: Composition and divergence of
coronavirus spike proteins and host ACE2 receptors predict
potential intermediate hosts of SARS-CoV-2. J Med Virol.
92:595–601. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu J, Zhao S, Teng T, Abdalla AE, Zhu W,
Xie L, Wang Y and Guo X: Systematic comparison of two
animal-to-human trans-mitted human coronaviruses: SARS-CoV-2 and
SARS-CoV. Viruses. 12:2442020. View Article : Google Scholar
|
|
11
|
Zheng J: SARS-CoV-2: An emerging
coronavirus that causes a global threat. Int J Biol Sci.
16:1678–1685. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Y, Peng F, Wang R, Yange M, Guan K,
Jiang T, Xu G, Sun J and Chang C: The deadly coronaviruses: The
2003 SARS pandemic and the 2020 novel coronavirus epidemic in
China. J Autoimmun. 109:1024342020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuen KS, Ye ZW, Fung SY, Chan CP and Jin
DY: SARS-CoV-2 and COVID-19: The most important research questions.
Cell Biosci. 10:402020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peyronnet V, Sibiude J, Deruelle P,
Huissoud C, Lescure X, Lucet JC, Mandelbrot L, Nisand I, Vayssière
C, Yazpandanah Y, et al: SARS-CoV-2 infection during pregnancy.
Information and proposal of management care. CNGOF Gynecol Obstet
Fertil Senol. 48:436–443. 2020.In French.
|
|
15
|
Jiang X, Rayner S and Luo MH: Does
SARS-CoV-2 has a longer incubation period than SARS and MERS? J Med
Virol. 92:476–478. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lai A, Bergna A, Acciarri C, Galli M and
Zehender G: Early phylogenetic estimate of the effective
reproduction number of SARS-CoV-2. J Med Virol. 92:675–679. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lai CC, Shih TP, Ko WC, Tang HJ and Hsueh
PR: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
and coronavirus disease-2019 (COVID-19): The epidemic and the
challenges. Int J Antimicrob Agents. 55:1059242020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Malik YA: Properties of coronavirus and
SARS-CoV-2. Malays J Pathol. 42:3–11. 2020.PubMed/NCBI
|
|
19
|
Yu X and Yang R: COVID-19 transmission
through asymptomatic carriers is a challenge to containment.
Influenza Other Respir Viruses. 14:474–475. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baltimore D: Expression of animal virus
genomes. Bacteriol Rev. 35:235–241. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Englund JA, Kim YJ and McIntosh K: Human
coronaviruses, including Middle East respiratory syndrome
coronavirus. Feigin and Cherry's textbook of pediatric infectious
disease. Cherry J, Demmler Harrison GJ, Kaplan SL, Steinbach WJ and
Hotez PJ: 8th edition. Elsevier Inc; Philadelphia, PA, pp: pp.
1846–1854. 2019
|
|
22
|
Park SE: Epidemiology, virology, and
clinical features of severe acute respiratory
syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin
Exp Pediatr. 63:119–124. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fehr AR and Perlman S: Coronaviruses: An
overview of their replication and pathogenesis. Methods Mol Biol.
1282:1–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Phan T: Genetic diversity and evolution of
SARS-CoV-2. Infect Genet Evol. 81:1042602020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Q, Zhang Y, Wu L, Niu S, Song C,
Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, et al: Structural and
functional basis of SARS-CoV-2 entry by using human ACE2. Cell.
181:894–904.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S,
Zhang Q, Shi X, Wang Q, Zhang L and Wang X: Structure of the
SARS-CoV-2 spike receptor-binding domain bound to the ACE2
receptor. Nature. 581:215–220. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cantuti-Castelvetri L, Ojha R, Pedro LD,
Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya
T, Anastasina M, et al: Neuropilin-1 facilitates SARS-CoV-2 cell
entry and infectivity. Science. 370:856–860. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daly JL, Simonetti B, Klein K, Chen KE,
Williamson MK, Antón-Plágaro C, Shoemark DK, Simón-Gracia L, Bauer
M, Hollandi R, et al: Neuropilin-1 is a host factor for SARS-CoV-2
infection. Science. 370:861–865. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Walls AC, Park YJ, Tortorici MA, Wall A,
McGuire AT and Veesler D: Structure, function, and antigenicity of
the SARS-CoV-2 spike glycoprotein. Cell. 181:281–292.e6. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou
J, Liu W, Bi Y and Gao GF: Epidemiology, genetic recombination, and
pathogenesis of coronaviruses. Trends Microbiol. 24:490–502. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Elfiky AA: SARS-CoV-2 RNA dependent RNA
polymerase (RdRp) targeting: An in silico perspective. J Biomol
Struct Dyn. 1–9. 2020.Epub ahead of print.
|
|
32
|
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y,
Zhang B, Li X, Zhang L, Peng C, et al: Structure of Mpro
from SARS-CoV-2 and discovery of its inhibitors. Nature.
82:289–293. 2020. View Article : Google Scholar
|
|
33
|
Neuman BW, Kiss G, Kunding AH, Bhella D,
Baksh MF, Connelly S, Droese B, Klaus JP, Makino S, Sawicki SG, et
al: A structural analysis of M protein in coronavirus assembly and
morphology. J Struct Biol. 174:11–22. 2011. View Article : Google Scholar
|
|
34
|
Vennema H, Godeke GJ, Rossen JW, Voorhout
WF, Horzinek MC, Opstelten DJ and Rottier PJ:
Nucleocapsid-independent assembly of coronavirus-like particles by
co-expression of viral envelope protein genes. EMBO J.
15:2020–2028. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Escors D, Ortego J, Laude H and Enjuanes
L: The membrane M protein carboxy terminus binds to transmissible
gastroenteritis coronavirus core and contributes to core stability.
J Virol. 75:1312–1324. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bourgonje AR, Abdulle AE, Timens W,
Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors
AA, Osterhaus AD, et al: Angiotensin-converting enzyme-2 (ACE2),
SARS-CoV-2 and the pathophysiology of coronavirus disease 2019
(COVID-19). J Pathol. 251:228–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang H, Penninger JM, Li Y, Zhong N and
Slutsky AS: Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2
receptor: Molecular mechanisms and potential therapeutic target.
Intensive Care Med. 46:586–590. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Castranova V, Rabovsky J, Tucker JH and
Miles PR: The alveolar type II epithelial cell: A multifunctional
pneumocyte. Toxicol Appl Pharmacol. 93:472–483. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rockx B, Kuiken T, Herfst S, Bestebroer T,
Lamers MM, Oude Munnink BB, de Meulder D, van Amerongen G, van den
Brand J, Okba NMA, et al: Comparative pathogenesis of COVID-19,
MERS, and SARS in a nonhuman primate model. Science. 368:1012–1015.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lukassen S, Chua RL, Trefzer T, Kahn NC,
Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, et
al: SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in
bronchial transient secretory cells. EMBO J. 39:e1051142020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chu H, Chan JF, Wang Y, Yuen TT, Chai Y,
Hou Y, Shuai H, Yang D, Hu B, Huang X, et al: Comparative
replication and immune activation profiles of SARS-CoV-2 and
SARS-CoV in human lungs: An ex vivo study with implications for the
patho-genesis of COVID-19. Clin Infect Dis. 71:1400–1409. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pachetti M, Marini B, Benedetti F, Giudici
F, Mauro E, Storici P, Masciovecchio C, Angeletti S, Ciccozzi M,
Gallo RC, et al: Emerging SARS-CoV-2 mutation hot spots include a
novel RNA-dependent-RNA polymerase variant. J Transl Med.
18:1792020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Holmes EA, O'Connor RC, Perry VH, Tracey
I, Wessely S, Arseneault L, Ballard C, Christensen H, Cohen Silver
R, Everall I, et al: Multidisciplinary research priorities for the
COVID-19 pandemic: A call for action for mental health science.
Lancet Psychiatry. 7:547–560. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Roussel Y, Giraud-Gatineau A, Jimeno MT,
Rolain JM, Zandotti C, Colson P and Raoult D: SARS-CoV-2: Fear
versus data. Int J Antimicrob Agents. 55:1059472020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
World Health Organization (WHO): WHO
Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/urisimplehttps://covid19.who.int/.
Retrieved November 17, 2020.
|
|
46
|
Sohrabi C, Alsafi Z, O'Neill N, Khan M,
Kerwan A, Al-Jabir A, Iosifidis C and Agha R: World Health
Organization declares global emergency: A review of the 2019 novel
coronavirus (COVID-19). Int J Surg. 76:71–76. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bulut C and Kato Y: Epidemiology of
COVID-19. Turk J Med Sci. 50:563–570. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
New York City Department of Health and
Mental Hygiene (DOHMH) COVID-19 Response Team: Preliminary estimate
of excess mortality during the COVID-19 outbreak-New York City,
March 11-May 2, 2020. MMWR Morb Mortal Wkly Rep. 69:603–605. 2020.
View Article : Google Scholar
|
|
49
|
The epidemiological characteristics of an
outbreak of 2019 novel coronavirus diseases (COVID-19) in China.
Zhonghua Liu Xing Bing Xue Za Zhi. 41:145–151. 2020.In Chinese.
|
|
50
|
Goh KJ, Choong MC, Cheong EH, Kalimuddin
S, Duu Wen S, Phua GC, Chan KS and Haja Mohideen S: Rapid
progression to acute respiratory distress syndrome: Review of
current under-standing of critical illness from COVID-19 infection.
Ann Acad Med Singap. 49:108–118. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Balasubramanian S, Rao NM, Goenka A,
Roderick M and Ramanan AV: Coronavirus Disease 2019 (COVID-19) in
children-what we know so far and what we do not? Indian Pediatr.
57:435–442. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zimmermann P and Curtis N: Coronavirus
infections in children including COVID-19: An overview of the
epidemiology, clinical features, diagnosis, treatment and
prevention options in children. Pediatr Infect Dis J. 39:355–368.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sharma G, Volgman AS and Michos ED: Sex
differences in mortality from COVID-19 pandemic: Are men vulnerable
and women protected? JACC Case Rep. 2:1407–1410. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu Y, Chen H, Tang K and Guo Y: Clinical
manifestations and outcome of SARS-CoV-2 infection during
pregnancy. J Infect. Mar 4–2020.Epub ahead of print.
|
|
55
|
Rasmussen SA, Smulian JC, Lednicky JA, Wen
TS and Jamieson DJ: Coronavirus Disease 2019 (COVID-19) and
pregnancy: What obstetricians need to know. Am J Obstet Gynecol.
222:415–426. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lescure FX, Bouadma L, Nguyen D, Parisey
M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati
F, Le Hingrat Q, et al: Clinical and virological data of the first
cases of COVID-19 in Europe: A case series. Lancet Infect Dis.
20:697–706. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Remuzzi A and Remuzzi G: COVID-19 and
Italy: What next? Lancet. 395:1225–1228. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Saglietto A, D'Ascenzo F, Zoccai GB and De
Ferrari GM: COVID-19 in Europe: The Italian lesson. Lancet.
395:1110–1111. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
COVID-19 Situazione in Italia. http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCorona-virus.jsp?lingua=italiano&id=5351&area=nuovoCoronavirus&menu=vuotourisimplehttp://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCorona-virus.jsp?lingua=italiano&id=5351&area=nuovoCoronavirus&menu=vuoto.
Retrieved May 29, 2020.
|
|
60
|
Saez M, Tobias A, Varga D and Barceló MA:
Effectiveness of the measures to flatten the epidemic curve of
COVID-19. The case of Spain. Sci Total Environ. 727:1387612020.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Update no. 120. Coronavirus disease
(COVID-19). 29–05. 2020, https://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_120_COVID-19.pdfurisimplehttps://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_120_COVID-19.pdf.
Retrieved May 29, 2020.
|
|
62
|
Castaldi S, Romano L, Pariani E, Garbelli
C and Biganzoli E: COVID-19: The end of lockdown what next? Acta
Biomed. 91:236–238. 2020.PubMed/NCBI
|
|
63
|
Mateos R, Fernández M, Franco M and
Sánchez M: COVID-19 in Spain. Coming back to the 'new normality'
after 2 months of confinement. Int Psychogeriatr. 32:1169–1172.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
World Health Organization (WHO): Dashboard
Italy From January 29 to 17 November 2020. https://covid19.who.int/region/euro/country/iturisimplehttps://covid19.who.int/region/euro/country/it.
|
|
65
|
World Health Organization (WHO): Dashboard
Spain From January 29 to 17 November 2020. https://covid19.who.int/region/euro/country/esurisimplehttps://covid19.who.int/region/euro/country/es.
|
|
66
|
International Monetary Fund Italy.
https://www.imf.org/en/Countries/ITAurisimplehttps://www.imf.org/en/Countries/ITA.
Retrieved 12 August 12, 2020.
|
|
67
|
International Monetary Fund Spain.
https://www.imf.org/en/Countries/ESP#countrydataurisimplehttps://www.imf.org/en/Countries/ESP#countrydata.
Retrieved August 12, 2020.
|
|
68
|
Nicola M, Alsafi Z, Sohrabi C, Kerwan A,
Al-Jabir A, Iosifidis C, Agha M and Agha R: The socio-economic
implications of the coronavirus pandemic (COVID-19): A review. Int
J Surg. 78:185–193. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rabaan AA, Al-Ahmed SH, Haque S, Sah R,
Tiwari R, Malik YS, Dhama K, Yatoo MI, Bonilla-Aldana DK and
Rodriguez-Morales AJ: SARS-CoV-2, SARS-CoV, and MERS-COV: A
comparative overview. Infez Med. 28:174–184. 2020.PubMed/NCBI
|
|
70
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associ-ated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Corman VM, Landt O, Kaiser M, Molenkamp R,
Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML,
et al: Detection of 2019 novel coronavirus (2019-nCoV) by real-time
RT-PCR. Euro Surveill. 25:20000452020. View Article : Google Scholar :
|
|
72
|
Chan JF, Yip CC, To KK, Tang TH, Wong SC,
Leung KH, Fung AY, Ng AC, Zou Z, Tsoi HW, et al: Improved molecular
diagnosis of COVID-19 by the novel, highly sensitive and specific
COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR assay
validated in vitro and with clinical specimens. J Clin Microbiol.
58:e00310–20. 2020. View Article : Google Scholar :
|
|
73
|
Artika IM, Wiyatno A and Ma'roef CN:
Pathogenic viruses: Molecular detection and characterization.
Infect Genet Evol. 81:1042152020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Dai WC, Zhang HW, Yu J, Xu HJ, Chen H, Luo
SP, Zhang H, Liang LH, Wu XL, Lei Y and Lin F: CT Imaging and
differential diagnosis of COVID-19. Can Assoc Radiol J. 71:195–200.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX,
Wang QZ, Sun C, Sylvia S, Rozelle S, Raat H and Zhou H:
Epidemiology, causes, clinical manifestation and diagnosis,
prevention and control of coronavirus disease (COVID-19) during the
early outbreak period: A scoping review. Infect Dis Poverty.
9:292020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Yan Y, Shin WI, Pang YX, Meng Y, Lai J,
You C, Zhao H, Lester E, Wu T and Pang CH: The First 75 Days of
Novel Coronavirus (SARS-CoV-2) Outbreak: Recent advances,
prevention, and treatment. Int J Environ Res Public Health.
17:23232020. View Article : Google Scholar :
|
|
77
|
Otter JA, Donskey C, Yezli S, Douthwaite
S, Goldenberg SD and Weber DJ: Transmission of SARS and MERS
coronaviruses and influenza virus in healthcare settings: The
possible role of dry surface contamination. J Hosp Infect.
92:235–250. 2016. View Article : Google Scholar
|
|
78
|
Dowell SF, Simmerman JM, Erdman DD, Wu JS,
Chaovavanich A, Javadi M, Yang JY, Anderson LJ, Tong S and Ho MS:
Severe acute respiratory syndrome coronavirus on hospital surfaces.
Clin Infect Dis. 39:652–657. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kampf G, Todt D, Pfaender S and Steinmann
E: Persistence of coronaviruses on inanimate surfaces and their
inactivation with biocidal agents. J Hosp Infect. 104:246–251.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
World Health Organization (WHO): Novel
Coronavirus (2019-nCoV) Advice for the public. WHO; Geneva:
2020
|
|
81
|
Güner R, Hasanoğlu I and Aktaş F:
COVID-19: Prevention and control measures in community. Turk J Med
Sci. 50:571–577. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kwon KT, Ko JH, Shin H, Sung M and Kim JY:
Drive-Through screening center for COVID-19: A safe and efficient
screening system against massive community outbreak. J Korean Med
Sci. 35:e1232020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lan L, Xu D, Ye G, Xia C, Wang S, Li Y and
Xu H: Positive RT-PCR test results in patients recovered from
COVID-19. JAMA. 323:1502–1503. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Nikolich-Zugich J, Knox KS, Rios CT, Natt
B, Bhattacharya D and Fain MJ: SARS-CoV-2 and COVID-19 in older
adults: What we may expect regarding pathogenesis, immune
responses, and outcomes. Geroscience. 42:505–514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Tay MZ, Poh CM, Rénia L, MacAry PA and Ng
LFP: The trinity of COVID-19: Immunity, inflammation and
intervention. Nat Rev Immunol. 20:363–374. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Shi Y, Wang Y, Shao C, Huang J, Gan J,
Huang X, Bucci E, Piacentini M, Ippolito G and Melino G: COVID-19
infection: The perspectives on immune responses. Cell Death Differ.
27:1451–1454. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ahmadpoor P and Rostaing L: Why the immune
system fails to mount an adaptive immune response to a COVID-19
infection. Transpl Int. 33:824–825. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Azkur AK, Akdis M, Azkur D, Sokolowska M,
van de Veen W, Brüggen MC, O'Mahony L, Gao Y, Nadeau K and Akdis
CA: Immune response to SARS-CoV-2 and mechanisms of
immuno-pathological changes in COVID-19. Allergy. 75:1564–1581.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
de Simone G and Mancusi C: Finding the
right time for anti-inflammatory therapy in COVID-19. Int J Infect
Dis. 101:247–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Shah VK, Firmal P, Alam A, Ganguly D and
Chattopadhyay S: Overview of immune response during SARS-CoV-2
infection: Lessons from the past. Front Immunol. 11:19492020.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Soy M, Keser G, Atagündüz P, Tabak F,
Atagündüz I and Kayhan S: Cytokine storm in COVID-19: Pathogenesis
and overview of anti-inflammatory agents used in treatment. Clin
Rheumatol. 39:2085–2094. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Siddiqi HK and Mehra MR: COVID-19 illness
in native and immunosuppressed states: A clinical-therapeutic
staging proposal. J Heart Lung Transplant. 39:405–407. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Prompetchara E, Ketloy C and Palaga T:
Immune responses in COVID-19 and potential vaccines: Lessons
learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol.
38:1–9. 2020.PubMed/NCBI
|
|
94
|
Hadjadj J, Yatim N, Barnabei L, Corneau A,
Boussier J, Smith N, Péré H, Charbit B, Bondet V, Chenevier-Gobeaux
C, et al: Impaired type I interferon activity and exacerbated
inflammatory responses in severe COVID-19 patients. Science.
369:718–724. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Tufan A, Avanoğlu Güler A and
Matucci-Cerinic M: COVID-19, immune system response,
hyperinflammation and repurposing antirheumatic drugs. Turk J Med
Sci. 50(SI-1): 620–632. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Gubernatorova EO, Gorshkova EA, Polinova
AI and Drutskaya MD: IL-6: Relevance for immunopathology of
SARS-CoV-2. Cytokine Growth Factor Rev. 53:13–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Xu Z, Shi L, Wang Y, Zhang J, Huang L,
Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al: Pathological findings
of COVID-19 associ-ated with acute respiratory distress syndrome.
Lancet Respir Med. 8:420–422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zhang B, Zhou X, Qiu Y, Song Y, Feng F,
Feng J, Song Q, Jia Q and Wang J: Clinical characteristics of 82
cases of death with COVID-19. PLoS One. 15:e02354582020. View Article : Google Scholar
|
|
99
|
He R, Lu Z, Zhang L, Fan T, Xiong R, Shen
X, Feng H, Meng H, Lin W, Jiang W and Geng Q: The clinical course
and its correlated immune status in COVID-19 pneumonia. J Clin
Virol. 127:1043612020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Coperchini F, Chiovato L, Croce L, Magri F
and Rotondi M: The cytokine storm in COVID-19: An overview of the
involvement of the chemokine/chemokine-receptor system. Cytokine
Growth Factor Rev. 53:25–32. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ye Q, Wang B and Mao J: The pathogenesis
and treatment of the ʻCytokine Storm' in COVID-19. J Infect.
80:607–613. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Li H, Liu L, Zhang D, Xu J, Dai H, Tang N,
Su X and Cao B: SARS-CoV-2 and viral sepsis: Observations and
hypotheses. Lancet. 395:1517–1520. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Li X and Ma X: Acute respiratory failure
in COVID-19: Is it 'typical' ARDS? Crit Care. 24:1982020.
View Article : Google Scholar
|
|
104
|
Hand TW, Vujkovic-Cvijin I, Ridaura VK and
Belkaid Y: Linking the microbiota, chronic disease, and the immune
system. Trends Endocrinol Metab. 27:831–843. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Stoian AP, Banerjee Y, Rizvi AA and Rizzo
M: Diabetes and the COVID-19 pandemic: How insights from recent
experience might guide future management. Metab Syndr Relat Disord.
18:173–175. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dietz W and Santos-Burgoa C: Obesity and
its implications for COVID-19 mortality. Obesity (Silver Spring).
28:10052020. View Article : Google Scholar
|
|
107
|
Ryan PM and Caplice NM: Is adipose tissue
a reservoir for viral spread, immune activation and cytokine
amplification in Coronavirus Disease 2019? Obesity (Silver Spring).
8:1191–1194. 2020. View Article : Google Scholar
|
|
108
|
Nikolich-Žugich J: The twilight of
immunity: Emerging concepts in aging of the immune system. Nat
Immunol. 19:10–19. 2018. View Article : Google Scholar
|
|
109
|
Butler MJ and Barrientos RM: The impact of
nutrition on COVID-19 susceptibility and long-term consequences.
Brain Behav Immun. 87:53–54. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Körner A, Schlegel M, Theurer J,
Frohnmeyer H, Adolph M, Heijink M, Giera M, Rosenberger P and
Mirakaj V: Resolution of inflammation and sepsis survival are
improved by dietary Ω-3 fatty acids. Cell Death Differ. 25:421–431.
2018. View Article : Google Scholar
|
|
111
|
Panigrahy D, Gilligan MM, Huang S, Gartung
A, Cortés-Puch I, Sime PJ, Phipps RP, Serhan CN and Hammock BD:
Inflammation resolution: A dual-pronged approach to averting
cytokine storms in COVID-19? Cancer Metastasis Rev. 39:337–340.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Chen P, Mao L, Nassis GP, Harmer P,
Ainsworth BE and Li F: Coronavirus disease (COVID-19): The need to
maintain regular physical activity while taking precautions. J
Sport Health Sci. 9:103–104. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Sardu C, Gambardella J, Morelli MB, Wang
X, Marfella R and Santulli G: Hypertension, thrombosis, kidney
failure, and diabetes: Is COVID-19 an endothelial disease? A
comprehensive evaluation of clinical and basic evidence. J Clin
Med. 9:E14172020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Guzik TJ, Mohiddin SA, Dimarco A, Patel V,
Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P,
D'Acquisto F, et al: COVID-19 and the cardiovascular system:
Implications for risk assessment, diagnosis, and treatment options.
Cardiovasc Res. 116:1666–1687. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Hamming I, Timens W, Bulthuis ML, Lely AT,
Navis G and van Goor H: Tissue distribution of ACE2 protein, the
functional receptor for SARS coronavirus. A first step in
understanding SARS pathogenesis. J Pathol. 203:631–637. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Varga Z, Flammer AJ, Steiger P, Haberecker
M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka
F and Moch H: Endothelial cell infection and endotheliitis in
COVID-19. Lancet. 395:1417–1418. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Alvarado-Moreno JA and Majluf-Cruz A:
COVID-19 and dysfunctional endothelium: The Mexican Scenario. Arch
Med Res. 51:587–588. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhou X, Zhu J and Xu T: Clinical
characteristics of corona-virus disease 2019 (COVID-19) patients
with hypertension on renin-angiotensin system inhibitors. Clin Exp
Hypertens. 42:656–660. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Bikdeli B, Madhavan MV, Jimenez D, Chuich
T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y,
et al: COVID-19 and thrombotic or thromboembolic disease:
Implications for prevention, antithrombotic therapy, and follow-up:
JACC State-of-the-Art Review. J Am Coll Cardiol. 75:2950–2973.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
von Brühl ML, Stark K, Steinhart A,
Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A,
Coletti R, Köllnberger M, et al: Monocytes, neutrophils, and
platelets cooperate to initiate and propagate venous thrombosis in
mice in vivo. J Exp Med. 209:819–835. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Gunzer M: Escaping the traps of your own
hunters. Science. 358:1126–1127. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
de Bont CM, Boelens WC and Pruijn GJM:
NETosis, complement, and coagulation: A triangular relationship.
Cell Mol Immunol. 16:19–27. 2019. View Article : Google Scholar :
|
|
123
|
Merad M and Martin JC: Pathological
inflammation in patients with COVID-19: A key role for monocytes
and macrophages. Nat Rev Immunol. 20:355–362. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Massberg S, Grahl L, von Bruehl ML,
Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov
K, Khandagale AB, et al: Reciprocal coupling of coagulation and
innate immunity via neutrophil serine proteases. Nat Med.
16:887–896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Oehmcke S, Mörgelin M and Herwald H:
Activation of the human contact system on neutrophil extracellular
traps. J Innate Immun. 1:225–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Semeraro F, Ammollo CT, Morrissey JH, Dale
GL, Friese P, Esmon NL and Esmon CT: Extracellular histones promote
thrombin generation through platelet-dependent mechanisms:
Involvement of platelet TLR2 and TLR4. Blood. 118:1952–1961. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Jiménez-Alcázar M, Rangaswamy C, Panda R,
Bitterling J, Simsek YJ, Long AT, Bilyy R, Krenn V, Renné C, Renné
T, et al: Host DNases prevent vascular occlusion by neutrophil
extracellular traps. Science. 358:1202–1206. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Lee KH, Cavanaugh L, Leung H, Yan F,
Ahmadi Z, Chong BH and Passam F: Quantification of NETs-associated
markers by flow cytometry and serum assays in patients with
thrombosis and sepsis. Int J Lab Hematol. 40:392–399. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Barnes BJ, Adrover JM, Baxter-Stoltzfus A,
Borczuk A, Cools-Lartigue J, Crawford JM, Daßler-Plenker J, Guerci
P, Huynh C, Knight JS, et al: Targeting potential drivers of
COVID-19: Neutrophil extracellular traps. J Exp Med.
217:e202006522020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zhang Y, Xiao M, Zhang S, Xia P, Cao W,
Jiang W, Chen H, Ding X, Zhao H, Zhang H, et al: Coagulopathy and
antiphos-pholipid antibodies in patients with covid-19. N Engl J
Med. 382:e382020. View Article : Google Scholar
|
|
131
|
Escher R, Breakey N and Lämmle B: Severe
COVID-19 infection associated with endothelial activation. Thromb
Res. 190:622020. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Whyte CS, Morrow GB, Mitchell JL, Chowdary
P and Mutch NJ: Fibrinolytic abnormalities in acute respiratory
distress syndrome (ARDS) and versatility of thrombolytic drugs to
treat COVID-19. J Thromb Haemost. 18:1548–1555. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Zhu J, Zhong Z, Ji P, Li H, Li B, Pang J,
Zhang J and Zhao C: Clinicopathological characteristics of 8697
patients with COVID-19 in China: A meta-analysis. Fam Med Community
Health. 8:e0004062020. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Novel Coronavirus-China. http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/urisimplewww.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
Retrieved May 30, 2020.
|
|
135
|
Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y,
Zhu H, Zhao W, Han Y and Qin C: From SARS to MERS, thrusting
coronavi-ruses into the spotlight. Viruses. 11:592019. View Article : Google Scholar
|
|
136
|
Fu J, Zhou B, Zhang L, Balaji KS, Wei C,
Liu X, Chen H, Peng J and Fu J: Expressions and significances of
the angiotensin-converting enzyme 2 gene, the receptor of
SARS-CoV-2 for COVID-19. Mol Biol Rep. 47:4383–4392. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Hui KPY, Cheung MC, Perera RAPM, Ng KC,
Bui CHT, Ho JCW, Ng MMT, Kuok DIT, Shih KC, Tsao SW, et al:
Tropism, replication competence, and innate immune responses of the
coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva:
An analysis in ex-vivo and in-vitro cultures. Lancet Respir Med.
8:687–695. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng
X, Li T and Chen Q: High expression of ACE2 receptor of 2019-nCoV
on the epithelial cells of oral mucosa. Int J Oral Sci. 12:82020.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Zhang H, Kang Z, Gong H, Xu D, Wang J, Li
Z, Li Z, Cui X, Xiao J, Zhan J, et al: Digestive system is a
potential route of COVID-19: An analysis of single-cell
coexpression pattern of key proteins in viral entry process. Gut.
69:1010–1018. 2020. View Article : Google Scholar :
|
|
140
|
Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu
Y, Liu Y, Wang X and Wang L: Diagnostic utility of clinical
laboratory data determinations for patients with the severe
COVID-19. J Med Virol. 92:791–796. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Wang Y, Kang H, Liu X and Tong Z:
Asymptomatic cases with SARS-CoV-2 infection. J Med Virol.
92:1401–1403. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Fu L, Wang B, Yuan T, Chen X, Ao Y,
Fitzpatrick T, Li P, Zhou Y, Lin YF, Duan Q, et al: Clinical
characteristics of coronavirus disease 2019 (COVID-19) in China: A
systematic review and meta-analysis. J Infect. 80:656–665. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Lian J, Jin X, Hao S, Jia H, Cai H, Zhang
X, Hu J, Zheng L, Wang X, Zhang S, et al: Epidemiological,
clinical, and virological characteristics of 465 hospitalized cases
of coronavirus disease 2019 (COVID-19) from Zhejiang province in
China. Influenza Other Respir Viruses. 14:564–574. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Gattinoni L, Chiumello D, Caironi P,
Busana M, Romitti F, Brazzi L and Camporota L: COVID-19 pneumonia:
Different respiratory treatments for different phenotypes?
Intensive Care Med. 46:1099–1102. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
The European Society for Cardiology (ESC):
ESC Guidance for the Diagnosis and Management of CV Disease during
the COVID-19 Pandemic. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESCCOVID-19-Guidanceurisimplehttps://www.escardio.org/Education/COVID-19-and-Cardiology/ESCCOVID-19-Guidance.
Last updated May 28, 2020.
|
|
146
|
Shang W, Dong J, Ren Y, Tian M, Li W, Hu J
and Li Y: The value of clinical parameters in predicting the
severity of COVID-19. J Med Virol. 92:2188–2192. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q,
He Q, Wang Z, Liu Y, Liu L, et al: Obesity and COVID-19 Severity in
a Designated Hospital in Shenzhen, China. Diabetes Care.
43:1392–1398. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Palaiodimos L, Kokkinidis DG, Li W,
Karamanis D, Ognibene J, Arora S, Southern WN and Mantzoros CS:
Severe obesity, increasing age and male sex are independently
associated with worse in-hospital outcomes, and higher in-hospital
mortality, in a cohort of patients with COVID-19 in the Bronx, New
York. Metabolism. 108:1542622020. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zhang L, Feng X, Zhang D, Jiang C, Mei H,
Wang J, Zhang C, Li H, Xia X, Kong S, et al: Deep vein thrombosis
in hospitalized patients with (COVID-19) in Wuhan, China:
Prevalence, risk factors, and outcome. Circulation. 142:114–128.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Stoneham SM, Milne KM, Nuttall E, Frew GH,
Sturrock BR, Sivaloganathan H, Ladikou EE, Drage S, Phillips B,
Chevassut TJ and Eziefula AC: Thrombotic risk in COVID-19: A case
series and case-control study. Clin Med (Lond). 20:e76–e81. 2020.
View Article : Google Scholar
|
|
151
|
Jin X, Lian JS, Hu JH, Gao J, Zheng L,
Zhang YM, Hao SR, Jia HY, Cai H, Zhang XL, et al: Epidemiological,
clinical and virological characteristics of 74 cases of
coronavirus-infected disease 2019 (COVID-19) with gastrointestinal
symptoms. Gut. 69:1002–1009. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Lin L, Jiang X, Zhang Z, Huang S, Zhang Z,
Fang Z, Gu Z, Gao L, Shi H, Mai L, et al: Gastrointestinal symptoms
of 95 cases with SARS-CoV-2 infection. Gut. 69:997–1001. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang
J, Shen J, Zhu LR, Chen Y, Iacucci M, et al: Manifestations and
prognosis of gastro-intestinal and liver involvement in patients
with COVID-19: A systematic review and meta-analysis. Lancet
Gastroenterol Hepatol. 5:667–678. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
To KK, Tsang OT, Yip CC, Chan KH, Wu TC,
Chan JM, Leung WS, Chik TS, Choi CY, Kandamby DH, et al: Consistent
detection of 2019 novel coronavirus in saliva. Clin Infect Dis.
71:841–843. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Holshue ML, DeBolt C, Lindquist S, Lofy
KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural
A, et al: First Case of 2019 Novel Coronavirus in the United
States. N Engl J Med. 382:929–936. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z,
Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: A retrospective cohort study. Lancet. 395:1054–1062. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Jiang SQ, Huang QF, Xie WM, Lv C and Quan
XQ: The association between severe COVID-19 and low platelet count:
Evidence from 31 observational studies involving 7613 participants.
Br J Haematol. 190. pp. e29–e33. 2020, View Article : Google Scholar
|
|
158
|
Doobay MF, Talman LS, Obr TD, Tian X,
Davisson RL and Lazartigues E: Differential expression of neuronal
ACE2 in transgenic mice with overexpression of the brain
renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol.
292:R373–R381. 2007. View Article : Google Scholar :
|
|
159
|
Liguori C, Pierantozzi M, Spanetta M,
Sarmati L, Cesta N, Iannetta M, Ora J, Mina GG, Puxeddu E, Balbi O,
et al: Subjective neurological symptoms frequently occur in
patients with SARS-CoV2 infection. Brain Behav Immun. 88:11–16.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung
J and Kim SH: Clinical characteristics of asymptomatic and
symptomatic patients with mild COVID-19. Clin Microbiol Infect.
26:948.e1–948.e3. 2020. View Article : Google Scholar
|
|
161
|
Ye M, Ren Y and Lv T: Encephalitis as a
clinical manifestation of COVID-19. Brain Behav Immun. 88:945–946.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Bernard-Valnet R, Pizzarotti B, Anichini
A, Demars Y, Russo E, Schmidhauser M, Cerutti-Sola J, Rossetti AO
and Du Pasquier R: Two patients with acute meningoencephalitis
concomitant to SARS-CoV-2 infection. Eur J Neurol. 27:e43–e44.
2020. View Article : Google Scholar
|
|
163
|
Moriguchi T, Harii N, Goto J, Harada D,
Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, et al:
A first case of meningitis/encephalitis associated with
SARS-Coronavirus-2. Int J Infect Dis. 94:55–58. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu
C, Ma Z, Huang Y, Liu W, Yao Y, et al: Renal involvement and early
prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol.
31:1157–1165. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Galván Casas C, Català A, Carretero
Hernández G, Rodríguez-Jiménez P, Fernández Nieto D,
Rodríguez-Villa Lario A, Navarro Fernández I, Ruiz-Villaverde R,
Falkenhain-López D, Llamas Velasco M, et al: Classification of the
cutaneous manifestations of COVID-19: A rapid prospective
nationwide consensus study in Spain with 375 cases. Br J Dermatol.
183:71–77. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Tang K, Wang Y, Zhang H, Zheng Q, Fang R
and Sun Q: Cutaneous manifestations of the Coronavirus Disease 2019
(COVID-19): A brief review. Dermatol Ther. 33:e135282020.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Chen L, Deng C, Chen X, Zhang X, Chen B,
Yu H, Qin Y, Xiao K, Zhang H and Sun X: Ocular manifestations and
clinical characteristics of 535 cases of COVID-19 in Wuhan, China:
a cross-sectional study. Acta Ophthalmol. 98:e951–e959. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Loffredo L, Pacella F, Pacella E, Tiscione
G, Oliva A and Violi F: Conjunctivitis and COVID-19: A
meta-analysis. J Med Virol. 92:1413–1414. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Panahi L, Amiri M and Pouy S: Clinical
characteristics of COVID-19 infection in newborns and pediatrics: A
systematic review. Arch Acad Emerg Med. 8:e502020.PubMed/NCBI
|
|
170
|
Mustafa NM and A Selim L: Characterisation
of COVID-19 Pandemic in Paediatric Age Group: A systematic review
and meta-analysis. J Clin Virol. 128:1043952020. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Liguoro I, Pilotto C, Bonanni M, Ferrari
ME, Pusiol A, Nocerino A, Vidal E and Cogo P: SARS-COV-2 infection
in children and newborns: A systematic review. Eur J Pediatr.
179:1029–1046. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang
FR and Liu ZS: Clinical features of severe pediatric patients with
coronavirus disease 2019 in Wuhan: A single center's observational
study. World J Pediatr. 16:251–259. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Juan J, Gil MM, Rong Z, Zhang Y, Yang H
and Poon LC: Effects of coronavirus disease 2019 (COVID-19) on
maternal, perinatal and neonatal outcomes: A systematic review.
Ultrasound Obstet Gynecol. 56:15–27. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Alzamora MC, Paredes T, Caceres D, Webb
CM, Valdez LM and La Rosa M: Severe COVID-19 during pregnancy and
possible vertical transmission. Am J Perinatol. 37:861–865. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Valdés G, Neves LA, Anton L, Corthorn J,
Chacón C, Germain AM, Merrill DC, Ferrario CM, Sarao R, Penninger J
and Brosnihan KB: Distribution of angiotensin-(1-7) and ACE2 in
human placentas of normal and pathological pregnancies. Placenta.
27:200–207. 2006. View Article : Google Scholar
|
|
176
|
Spanish Ministry: Available treatments
subjected to special access conditions for the managing of the
respiratory infection by SARS-CoV-2. Spanish Agency for Medicines
and Health Products; 2020, https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%E2%80%9119/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/?lang=enurisimplehttps://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%E2%80%9119/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/?lang=en.
Retrieved May 28, 2020.
|
|
177
|
World Health Organization (WHO): Clinical
management of COVID-19: interim guidance. https://apps.who.int/iris/handle/10665/332196urisimplehttps://apps.who.int/iris/handle/10665/332196.
License: CC BY-NC-SA 3.0 IGO Accessed May 27, 2020.
|
|
178
|
Wu R, Wang L, Kuo HD, Shannar A, Peter R,
Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, et al: An update on
current therapeutic drugs treating COVID-19. Curr Pharmacol Rep.
May 11–2020.Epub ahead for print. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Zhou M, Zhang X and Qu J: Coronavirus
disease 2019 (COVID-19): A clinical update. Front Med. 14:126–135.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Dima A, Balaban DV, Jurcut C, Berza I,
Jurcut R and Jinga M: Physicians' Perspectives on COVID-19: An
International Survey. Healthcare (Basel). 8:2502020. View Article : Google Scholar
|
|
181
|
Jawhara S: Could intravenous
immunoglobulin collected from recovered coronavirus patients
protect against COVID-19 and strengthen the immune system of new
patients? Int J Mol Sci. 21:22722020. View Article : Google Scholar :
|
|
182
|
Qiu T, Liang S, Dabbous M, Wang Y, Han R
and Toumi M: Chinese guidelines related to novel coronavirus
pneumonia. J Mark Access Health Policy. 8:18184462020. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Gutiérrez-Lorenzo M and Cuadros-Martínez
CM: Baricitinib in treatment of SARS-CoV-2 infection. Rev Esp
Quimioter. 33:294–295. 2020.In Spanish. View Article : Google Scholar
|
|
184
|
Singh AK, Majumdar S, Singh R and Misra A:
Role of corticosteroid in the management of COVID-19: A systemic
review and a Clinician's perspective. Diabetes Metab Syndr.
14:971–978. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Mulangu S, Dodd LE, Davey RT Jr, Tshiani
Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D,
Tshomba Oloma A, Ibanda A, et al: A randomized, controlled trial of
Ebola virus disease therapeutics. N Engl J Med. 381:2293–2303.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
de Wit E, Feldmann F, Cronin J, Jordan R,
Okumura A, Thomas T, Scott D, Cihlar T and Feldmann H: Prophylactic
and therapeutic remdesivir (GS-5734) treatment in the rhesus
macaque model of MERS-CoV infection. Proc Natl Acad Sci USA.
117:6771–6776. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Lo MK, Feldmann F, Gary JM, Jordan R,
Bannister R, Cronin J, Patel NR, Klena JD, Nichol ST, Cihlar T, et
al: Remdesivir (GS-5734) protects African green monkeys from Nipah
virus challenge. Sci Transl Med. 11:eaau92422019. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Grein J, Ohmagari N, Shin D, Diaz G,
Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, et
al: Compassionate use of remdesivir for patients with severe
Covid-19. N Engl J Med. 382:2327–2336. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Ferner RE and Aronson JK: Remdesivir in
covid-19. BMJ. m1610:3692020.
|
|
190
|
Jean SS, Lee PI and Hsueh PR: Treatment
options for COVID-19: The reality and challenges. J Microbiol
Immunol Infect. 53:436–443. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Groneberg DA, Poutanen SM, Low DE, Lode H,
Welte T and Zabel P: Treatment and vaccines for severe acute
respiratory syndrome. Lancet Infect Dis. 5:147–155. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan
G, Ruan L, Song B, Cai Y, Wei M, et al: A Trial of
Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N
Engl J Med. 382:1787–1799. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Kunz KM: A Trial of Lopinavir-Ritonavir in
Covid-19. N Engl J Med. 382:e682020. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Statement from the Chief Investigators of
the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on
lopinavir-ritonavir. https://www.recoverytrial.net/files/lopi-navir-ritonavir-recovery-statement-29062020_final.pdfurisimplehttps://www.recoverytrial.net/files/lopi-navir-ritonavir-recovery-statement-29062020_final.pdf
Accessed June 29, 2020.
|
|
195
|
Al-Bari MA: Chloroquine analogues in drug
discovery: New directions of uses, mechanisms of actions and toxic
manifestations from malaria to multifarious diseases. J Antimicrob
Chemother. 70:1608–1621. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Vincent MJ, Bergeron E, Benjannet S,
Erickson BR, Rollin PE, Ksiazek TG, Seidah NG and Nichol ST:
Chloroquine is a potent inhibitor of SARS coronavirus infection and
spread. Virol J. 2:692005. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu
M, Shi Z, Hu Z, Zhong W and Xiao G: Remdesivir and chloroquine
effectively inhibit the recently emerged novel coronavirus
(2019-nCoV) in vitro. Cell Res. 30:269–271. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Andreani J, Le Bideau M, Duflot I, Jardot
P, Rolland C, Boxberger M, Wurtz N, Rolain JM, Colson P, La Scola B
and Raoult D: In vitro testing of combined hydroxychloroquine and
azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog.
145:1042282020. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Gautret P, Lagier JC, Parola P, Hoang V,
Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira V,
et al: Hydroxychloroquine and azithromycin as a treatment of
COVID-19: Results of an open- label non-randomized clinical trial.
Int J Antimicrob Agents. 56:1059492020. View Article : Google Scholar
|
|
200
|
Molina JM, Delaugerre C, Goff JL,
Mela-Lima B, Ponscarme D, Goldwirt L and de Castro N: No evidence
of rapid antiviral clearance or clinical benefit with the
combination of hydroxy-chloroquine and azithromycin in patients
with severe COVID-19 infection. Med Mal Infect. 50:3842020.
View Article : Google Scholar
|
|
201
|
Rosenberg ES, Dufort EM, Udo T,
Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse
A, DeHovitz J, et al: Association of treatment with
hydroxychloroquine or azithro-mycin with in-hospital mortality in
patients with COVID-19 in New York State. JAMA. 323:2493–2502.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Hornby P and Landray M: Statement from the
Chief Investigators of the Randomised Evaluation of COVid-19
thERapY (RECOVERY) Trial on hydroxychloroquine. https://www.recov-erytrial.net/files/hcq-recovery-statement-050620-final-002.pdfurisimplehttps://www.recov-erytrial.net/files/hcq-recovery-statement-050620-final-002.pdf.
Accessed June 5, 2020.
|
|
203
|
Mansourabadi AH, Sadeghalvad M,
Mohammadi-Motlagh HR and Rezaei N: The immune system as a target
for therapy of SARS-CoV-2: A systematic review of the current
immunotherapies for COVID-19. Life Sci. 258:1181852020. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Aouba A, Baldolli A, Geffray L, Verdon R,
Bergot E, Martin-Silva N and Justet A: Targeting the inflammatory
cascade with anakinra in moderate to severe COVID-19 pneu-monia:
Case series. Ann Rheum Dis. 79:1381–1382. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Zhang C, Wu Z, Li JW, Zhao H and Wang GQ:
Cytokine release syndrome in severe COVID-19: Interleukin-6
receptor antago-nist Tocilizumab may be the key to reduce the
mortality. Int J Antimicrob Agents. 55:1059542020. View Article : Google Scholar
|
|
206
|
Sheppard M, Laskou F, Stapleton PP, Hadavi
S and Dasgupta B: Tocilizumab (Actemra). Hum Vaccin Immunother.
13:1972–1988. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Vastert SJ, Jamilloux Y, Quartier P,
Ohlman S, Osterling Koskinen L, Kullenberg T, Franck-Larsson K,
Fautrel B and de Benedetti F: Anakinra in children and adults with
Still's disease. Rheumatology (Oxford). 58(Suppl 6): vi9–vi22.
2018. View Article : Google Scholar
|
|
208
|
Guaraldi G, Meschiari M, Cozzi-Lepri A,
Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G,
Borghi V, et al: Tocilizumab in patients with severe COVID-19: A
retrospective cohort study. Lancet Rheumatol. 2:e474–e484. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Tomasiewicz K, Piekarska A,
Stempkowska-Rejek J, Serafińska S, Gawkowska A, Parczewski M,
Niścigorska-Olsen J, Lstrok;apiński TW, Zarębska-Michaluk D,
Kowalska JD, et al: Tocilizumab for patients with severe COVID-19:
A retrospective, multi-center study. Expert Rev Anti Infect Ther.
Aug 1–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Cauchois R, Koubi M, Delarbre D, Manet C,
Carvelli J, Blasco VB, Jean R, Fouche L, Bornet C, Pauly V, et al:
Early IL-1 receptor blockade in severe inflammatory respiratory
failure complicating COVID-19. Proc Natl Acad Sci USA.
117:18951–18953. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
McGonagle D, Sharif K, O'Regan A and
Bridgewood C: The role of cytokines including interleukin-6 in
COVID-19 induced pneumonia and macrophage activation syndrome-like
disease. Autoimmun Rev. 19:1025372020. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Xu X, Han M, Li T, Sun W, Wang D, Fu B,
Zhou Y, Zheng X, Yang Y, Li X, et al: Effective treatment of severe
COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA.
117:10970–10975. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Alzghari SK and Acuña VS: Supportive
treatment with tocilizumab for COVID-19: A systematic review. J
Clin Virol. 127:1043802020. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Galimberti S, Baldini C, Baratè C, Ricci
F, Balducci S, Grassi S, Ferro F, Buda G, Benedetti E, Fazzi R, et
al: The CoV-2 outbreak: How hematologists could help to fight
Covid-19. Pharmacol Res. 157:1048662020. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Peterson D, Damsky W and King B: The use
of Janus kinase inhibitors in the time of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). J Am Acad Dermatol.
82:e223–e226. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Chang R, Ng TB and Sun WZ: Lactoferrin as
potential preventative and adjunct treatment for COVID-19. Int J
Antimicrob Agents. 56:1061182020. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Ucciferri C, Barone M, Vecchiet J and
Falasca K: Pidotimod in paucisymptomatic SARS-CoV2 infected
patients. Mediterr J Hematol Infect Dis. 12:e20200482020.
View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Colunga Biancatelli RML, Berrill M,
Catravas JD and Marik PE: Quercetin and vitamin C: An experimental,
synergistic therapy for the prevention and treatment of SARS-CoV-2
related disease (COVID-19). Front Immunol. 11:14512020. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Mettenleiter TC: Chapter One-The First
'Virus Hunters'. Advances in Virus Research. Beer M and Höper D:
Academic Press; pp. 1–16. 2017
|
|
220
|
Goldsmith CS and Miller SE: Modern uses of
electron microscopy for detection of viruses. Clin Microbiol Rev.
22:552–563. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Singh L, Kruger HG, Maguire GEM, Govender
T and Parboosing R: The role of nanotechnology in the treatment of
viral infections. Ther Adv Infect Dis. 4:105–131. 2017.PubMed/NCBI
|
|
222
|
Sivasankarapillai VS, Pillai AM, Rahdar A,
Sobha AP, Das SS, Mitropoulos AC, Mokarrar MH and Kyzas GZ: On
facing the SARS-CoV-2 (COVID-19) with combination of nanomaterials
and medicine: Possible strategies and first challenges.
Nanomaterials (Basel). 10:8522020. View Article : Google Scholar
|
|
223
|
Kostarelos K: Nanoscale nights of
COVID-19. Nat Nanotechnol. 15:343–344. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Patra JK, Das G, Fraceto LF, Campos EV R,
Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R,
Swamy MK, Sharma S, et al: Nano based drug delivery systems: Recent
developments and future prospects. J Nanobiotechnology. 16:712018.
View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Chen L and Liang J: An overview of
functional nanoparticles as novel emerging antiviral therapeutic
agents. Mater Sci Eng C Mater Biol Appl. 112:1109242020. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Cui H, Webber MJ and Stupp SI:
Self-assembly of peptide amphiphiles: From molecules to
nanostructures to biomaterials. Biopolymers. 94:1–18. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Dormont F, Brusini R, Cailleau C, Reynaud
F, Peramo A, Gendron A, Mougin J, Gaudin F, Varna M and Couvreur P:
Squalene-based multidrug nanoparticles for improved mitigation of
uncontrolled inflammation. Sci Adv. 6:eaaz54662020. View Article : Google Scholar
|
|
228
|
Hu Y, Liu C and Muyldermans S:
Nanobody-based delivery systems for diagnosis and targeted tumor
therapy. Front Immunol. 8:14422017. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Walter JD, Hutter CAJ, Zimmermann I, Earp
J, Egloff P, Sorgenfrei M, Hürlimann LM, Gonda I, Meier G, Remm S,
et al: Synthetic nanobodies targeting the SARS-CoV-2
receptor-binding domain. BioRxiv. 1–18. 2020.
|
|
230
|
Ura T, Okuda K and Shimada M: Developments
in viral vector-based vaccines. Vaccines (Basel). 2:624–641. 2014.
View Article : Google Scholar
|
|
231
|
Xu H, Li Z and Si J: Nanocarriers in gene
therapy: A review. J Biomed Nanotechnol. 10:3483–3507. 2014.
View Article : Google Scholar
|
|
232
|
Feldman RA, Fuhr R, Smolenov I, Ribeiro A,
Panther L, Watson M, Senn JJ, Smith M, Almarsson Ӧ, Pujar HS, et
al: mRNA vaccines against H10N8 and H7N9 influenza viruses of
pandemic potential are immunogenic and well tolerated in healthy
adults in phase 1 randomized clinical trials. Vaccine.
37:3326–3334. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
McKay PF, Hu K, Blakney AK, Samnuan K,
Bouton CR, Rogers P, Polra K, Lin PJC, Barbosa C, Tam Y and
Shattock RJ: Self-amplifying RNA SARS-CoV-2 lipid nanoparticle
vaccine induces equivalent preclinical antibody titers and viral
neutralization to recovered COVID-19 patients. https://doi.org/10.1101/2020.04.22.055608urisimplehttps://doi.org/10.1101/2020.04.22.055608.
|
|
234
|
Raghunandan R, Lu H, Zhou B, Xabier MG,
Massare MJ, Flyer DC, Fries LF, Smith GE and Glenn GM: An insect
cell derived respiratory syncytial virus (RSV) F nanoparticle
vaccine induces antigenic site II antibodies and protects against
RSV challenge in cotton rats by active and passive immunization.
Vaccine. 32:6485–6492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
He L, de Val N, Morris CD, Vora N, Thinnes
TC, Kong L, Azadnia P, Sok D, Zhou B, Burton DR, et al: Presenting
native-like trimeric HIV-1 antigens with self-assembling
nanoparticles. Nat Commun. 7:120412016. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Foundation TWN: COVID-19 testing report
& analysis, 2020. http://www.worldnanofoundation.com/covid-19-report-analysisurisimplewww.worldnanofoundation.com/covid-19-report-analysis
Accessed July 24, 2020.
|
|
237
|
Zhao Z, Cui H, Song W, Ru X, Zhou W and Yu
X: A simple magnetic nanoparticles-based viral RNA extraction
method for efficient detection of SARS-CoV-2. bioRxiv. https://doi.org/10.1101/2020.02.22.961268urisimplehttps://doi.org/10.1101/2020.02.22.961268.
|
|
238
|
Wang M, Fu A, Hu B, Tong Y, Liu R, Liu Z,
Gu J, Xiang B, Liu J, Jiang W, et al: Nanopore target sequencing
for accurate and comprehensive detection of SARS-CoV-2 and other
respiratory viruses. Small. 16:e20021692020. View Article : Google Scholar
|
|
239
|
Lüthy IA, Ritacco V and Kantor IN: One
hundred years after the 'Spanish' flu. Medicina (B Aires).
78:113–118. 2018.In Spanish.
|
